JOSÉ JAVIER
FERNÁNDEZ RUIZ
Catedrático de universidad
Consiglio Nazionale delle Ricerche
Roma, ItaliaPublications in collaboration with researchers from Consiglio Nazionale delle Ricerche (19)
2023
-
Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice
Journal of neuroinflammation, Vol. 20, Núm. 1, pp. 108
2018
-
Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB1 receptor ligand antagonists
Bioorganic and Medicinal Chemistry, Vol. 26, Núm. 1, pp. 295-307
2016
-
Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome
Pharmacology Research and Perspectives, Vol. 4, Núm. 2
2015
-
Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders
Journal of Neuroimmune Pharmacology, Vol. 10, Núm. 2, pp. 233-244
2014
-
Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders
Epilepsia, Vol. 55, Núm. 6, pp. 791-802
2013
-
Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors
Multiple Sclerosis Journal, Vol. 19, Núm. 14, pp. 1896-1904
-
The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: A potential role of cyclooxygenase-2-dependent metabolism of 2-AG
Cell Death and Disease, Vol. 4, Núm. 10
2009
-
Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB1 receptor in different brain areas
Drug and Alcohol Dependence, Vol. 99, Núm. 1-3, pp. 354-358
2005
-
Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease
Brain Research, Vol. 1050, Núm. 1-2, pp. 210-216
-
Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis
Neurobiology of Disease, Vol. 20, Núm. 2, pp. 207-217
-
Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels
Biochemical Pharmacology, Vol. 70, Núm. 3, pp. 446-452
2004
-
Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse
British Journal of Pharmacology, Vol. 143, Núm. 4, pp. 455-464
2003
-
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease
Journal of Neurochemistry, Vol. 84, Núm. 5, pp. 1097-1109
2002
-
Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine
Brain Research, Vol. 954, Núm. 1, pp. 73-81
2001
-
Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues
European Journal of Pharmacology, Vol. 420, Núm. 2-3, pp. 123-131
2000
-
Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of Δ9- tetrahydrocannabinol-tolerant rats
Journal of Neurochemistry, Vol. 74, Núm. 4, pp. 1627-1635
-
Sex steroid influence on cannabinoid CB1 receptor mRNA and endocannabinoid levels in the anterior pituitary gland
Biochemical and Biophysical Research Communications, Vol. 270, Núm. 1, pp. 260-266
1999
-
Brain regional distribution of endocannabinoids: Implications for their biosynthesis and biological function
Biochemical and Biophysical Research Communications, Vol. 256, Núm. 2, pp. 377-380
-
Identification of endocannabinoids and cannabinoid CB1 receptor mRNA in the pituitary gland
Neuroendocrinology, Vol. 70, Núm. 2, pp. 137-145